SCHEMBL24619360

SCHEMBL24619360

CNC(=O)c1ccc(C(=O)CBr)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.43
HDAC6 Q9UBN7 5/20 0.41
HDAC1 Q13547 3/20 0.41
PLK1 P53350 5/20 0.41
GAA P10253 1/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC2 Q92769 1/20 0.41
THRB P10828 1/20 0.40
BRD4 O60885 1/20 0.40
BRD2 P25440 1/20 0.40
BRD3 Q15059 1/20 0.40
BRDT Q58F21 1/20 0.40
PLAU P00749 1/20 0.40
GSK3B P49841 1/20 0.40
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31604442 0.88 GAA (0.49) PTPN1HDAC6HDAC1PLK1GAA
SCHEMBL29306646 0.83 GAA (0.58) HDAC6HDAC1PLK1GAAHDAC8
SCHEMBL7920331 0.81 KDM4E (0.49) PTPN1GAAGSK3BKDM4EHPGD
SCHEMBL24619359 0.80 HDAC6 (0.46) HDAC6HDAC1PLK1GAAHDAC8
SCHEMBL10757078 0.79 HPGDS (0.49) PLK1GAAHDAC2GSK3BKDM4E
SCHEMBL28642724 0.79 HDAC6 (0.41) PTPN1HDAC6HDAC1PLK1GAA
SCHEMBL25095347 0.79 DGAT1 (0.47) PTPN1GSK3B
SCHEMBL16465920 0.79 DGAT1 (0.51) HDAC6HDAC1PLK1GAAHDAC8
SCHEMBL28543300 0.78 THRB (0.45) HDAC6HDAC1PLK1HDAC8HDAC2
SCHEMBL1355313 0.76 CA12 (0.50) PTPN1HDAC6HDAC1HDAC8HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 EP disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 CN disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 PTPN1 3379/4885HDAC6 1919/4885HDAC1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.